We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+1.32%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$134M
AUM Growth
+$13.4M
Cap. Flow
+$4.15M
Cap. Flow %
3.1%
Top 10 Hldgs %
78.52%
Holding
20
New
1
Increased
10
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$8.25M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.93M
3
CYTK icon
Cytokinetics
CYTK
+$3.5M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.32M
5
KALV
KalVista Pharmaceuticals
KALV
+$3M

Top Sells

Rank Stock Value
1
ALBO
Albireo Pharma Inc
ALBO
+$6.86M
2
TSVT
2seventy bio
TSVT
+$5.86M
3
APLS
Apellis Pharmaceuticals
APLS
+$5.14M
4
ARQT icon
Arcutis Biotherapeutics
ARQT
+$4.47M
5
FOLD
Amicus Therapeutics
FOLD
+$3.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
1
DELISTED
Cymabay Therapeutics
CBAY
$14.2M 10.61%
1,629,464
+17,686
+1% +$142K
CRNX icon
2
Crinetics Pharmaceuticals
CRNX
$8.87B
$11.9M 8.89%
741,043
+117,224
+19% +$2.17M
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.7M 8.76%
506,818
+83,641
+20% +$1.99M
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$10.8M 8.09%
99,217
+30,047
+43% +$3.32M
BIIB icon
5
Biogen
BIIB
$29.5B
$10.4M 7.78%
37,459
+29,799
+389% +$8.25M
CYTK icon
6
Cytokinetics
CYTK
$10.9B
$9.95M 7.44%
282,886
+85,904
+44% +$3.5M
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.43B
$9.7M 7.25%
1,163,535
+823,372
+242% +$7.93M
MORF
8
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$9.28M 6.93%
246,616
-23,211
-9% -$855K
KALV
9
DELISTED
KalVista Pharmaceuticals
KALV
$8.82M 6.59%
1,121,982
+402,045
+56% +$3M
ASND icon
10
Ascendis Pharma A/S
ASND
$16.6B
$8.28M 6.18%
77,210
+8,806
+13% +$1.01M
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
$8.12M 6.07%
123,165
-89,164
-42% -$5.14M
ITOS
12
DELISTED
iTeos Therapeutics
ITOS
$6.54M 4.89%
480,653
+138,582
+41% +$2.48M
SAGE
13
DELISTED
Sage Therapeutics
SAGE
$6.08M 4.54%
145,018
-11,067
-7% -$476K
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$2.86M 2.14%
258,288
-307,891
-54% -$3.8M
ARQT icon
15
Arcutis Biotherapeutics
ARQT
$3.48B
$1.96M 1.46%
178,217
-308,962
-63% -$4.47M
TSVT
16
DELISTED
2seventy bio
TSVT
$1.76M 1.31%
172,188
-512,808
-75% -$5.86M
ATXS
17
DELISTED
Astria Therapeutics
ATXS
$1.35M 1.01%
101,339
-68,154
-40% -$921K
SCLX icon
18
Scilex Holding
SCLX
$49.4M
$85.2K 0.06%
+297
New +$82.4K
TBPH icon
19
Theravance Biopharma
TBPH
$874M
– –
-141,339
Closed -$1.33M
ALBO
20
DELISTED
Albireo Pharma Inc
ALBO
– –
-341,827
Closed -$6.86M

Similar funds

LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $552M AUM 22.73% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $553M AUM 26.47% 1-Year Est. Return

Saturn V Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Saturn V Capital Management held 20 positions worth $134M, up 11% from $121M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Saturn V Capital Management deployed $4.15M of net new capital in Q1 2023, opening 1 new position and adding to 10 existing holdings. Its largest new stake was Scilex Holding: 297 shares worth $85.2K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was 2seventy bio, an estimated $5.86M trimmed.

  • Saturn V Capital Management's largest Q1 2023 buy was Scilex Holding: 297 shares worth $85.2K.
  • Saturn V Capital Management added most to Biogen in Q1 2023, an estimated $8.25M increase.
  • Saturn V Capital Management's biggest Q1 2023 reduction was 2seventy bio, cutting an estimated $5.86M.
  • Saturn V Capital Management fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $6.86M.
  • Saturn V Capital Management's ten largest holdings make up 79% of its $134M portfolio in Q1 2023.
  • Saturn V Capital Management opened 1 new position and closed 2 in Q1 2023.
  • Saturn V Capital Management's portfolio value rose 11% quarter-over-quarter to $134M.

Based on Saturn V Capital Management's 13F filing for Q1 2023, filed 15 May 2023.